Association between the CHEK2*1100delC germ line mutation and estrogen receptor status

G.H. de Bock; M.J. Mourits; M. Schutte; E.M. Krol-Warmerdam; C. Seynaeve; J. Blom; C.T. Brekelmans; H. Meijers-Heijboer; C.J. van Asperen; C.J. Cornelisse; P. Devilee; R.A. Tollenaar; J.G. Klijn

Association between the CHEK2*1100delC germ line mutation and estrogen receptor status

G.H. de Bock, M.J. Mourits, M. Schutte, E.M. Krol-Warmerdam, C. Seynaeve, J. Blom, C.T. Brekelmans, H. Meijers-Heijboer, C.J. van Asperen, C.J. Cornelisse, P. Devilee, R.A. Tollenaar, J.G. Klijn

Onderzoeksoutput › Academic

15 Citaten (Scopus)

Samenvatting

Already published data were further analyzed regarding the association between the CHEK2*1100delC germ line mutation and estrogen receptor (ER) status in patients with breast cancer. The CHEK2*1100delC mutation was more prevalent among the patients with a positive ER status (4.2% versus 1.0%). An ER-negative status was beside CHEK2*1100delC mutation and independently associated with an earlier of age onset of breast cancer. There was a trend that an ER-negative status, beside the presence of a CHEK2*1100delC mutation, was associated with a worse disease-free survival. There might be an association between ER status and a CHEK2*1100delC mutation. More studies with larger number of patients are needed to further investigate the relation between CHEK2*1100delC and ER status

Originele taal-2	English
Pagina's (van-tot)	552-555
Aantal pagina's	4
Tijdschrift	International Journal of Gynecological Cancer
Volume	16 Suppl 2
Status	Published - 2006

Handle.net

Permanente koppeling

Citeer dit

de Bock, G. H., Mourits, M. J., Schutte, M., Krol-Warmerdam, E. M., Seynaeve, C., Blom, J., Brekelmans, C. T., Meijers-Heijboer, H., van Asperen, C. J., Cornelisse, C. J., Devilee, P., Tollenaar, R. A., & Klijn, J. G. (2006). Association between the CHEK2*1100delC germ line mutation and estrogen receptor status. International Journal of Gynecological Cancer, 16 Suppl 2, 552-555.

@article{cbe65da86e984eb5a130917ad76d6edb,

title = "Association between the CHEK2*1100delC germ line mutation and estrogen receptor status",

abstract = "Already published data were further analyzed regarding the association between the CHEK2*1100delC germ line mutation and estrogen receptor (ER) status in patients with breast cancer. The CHEK2*1100delC mutation was more prevalent among the patients with a positive ER status (4.2% versus 1.0%). An ER-negative status was beside CHEK2*1100delC mutation and independently associated with an earlier of age onset of breast cancer. There was a trend that an ER-negative status, beside the presence of a CHEK2*1100delC mutation, was associated with a worse disease-free survival. There might be an association between ER status and a CHEK2*1100delC mutation. More studies with larger number of patients are needed to further investigate the relation between CHEK2*1100delC and ER status",

author = "{de Bock}, G.H. and M.J. Mourits and M. Schutte and E.M. Krol-Warmerdam and C. Seynaeve and J. Blom and C.T. Brekelmans and H. Meijers-Heijboer and {van Asperen}, C.J. and C.J. Cornelisse and P. Devilee and R.A. Tollenaar and J.G. Klijn",

year = "2006",

language = "English",

volume = "16 Suppl 2",

pages = "552--555",

journal = "International Journal of Gynecological Cancer",

issn = "1048-891X",

publisher = "LIPPINCOTT WILLIAMS & WILKINS",

}

TY - JOUR

T1 - Association between the CHEK2*1100delC germ line mutation and estrogen receptor status

AU - de Bock, G.H.

AU - Mourits, M.J.

AU - Schutte, M.

AU - Krol-Warmerdam, E.M.

AU - Seynaeve, C.

AU - Blom, J.

AU - Brekelmans, C.T.

AU - Meijers-Heijboer, H.

AU - van Asperen, C.J.

AU - Cornelisse, C.J.

AU - Devilee, P.

AU - Tollenaar, R.A.

AU - Klijn, J.G.

PY - 2006

Y1 - 2006

N2 - Already published data were further analyzed regarding the association between the CHEK2*1100delC germ line mutation and estrogen receptor (ER) status in patients with breast cancer. The CHEK2*1100delC mutation was more prevalent among the patients with a positive ER status (4.2% versus 1.0%). An ER-negative status was beside CHEK2*1100delC mutation and independently associated with an earlier of age onset of breast cancer. There was a trend that an ER-negative status, beside the presence of a CHEK2*1100delC mutation, was associated with a worse disease-free survival. There might be an association between ER status and a CHEK2*1100delC mutation. More studies with larger number of patients are needed to further investigate the relation between CHEK2*1100delC and ER status

AB - Already published data were further analyzed regarding the association between the CHEK2*1100delC germ line mutation and estrogen receptor (ER) status in patients with breast cancer. The CHEK2*1100delC mutation was more prevalent among the patients with a positive ER status (4.2% versus 1.0%). An ER-negative status was beside CHEK2*1100delC mutation and independently associated with an earlier of age onset of breast cancer. There was a trend that an ER-negative status, beside the presence of a CHEK2*1100delC mutation, was associated with a worse disease-free survival. There might be an association between ER status and a CHEK2*1100delC mutation. More studies with larger number of patients are needed to further investigate the relation between CHEK2*1100delC and ER status

M3 - Article

VL - 16 Suppl 2

SP - 552

EP - 555

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

ER -